Stifel downgraded Pliant Therapeutics (PLRX) to Hold from Buy with a price target of $3, down from $32.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRX:
- Leerink downgrades Pliant Therapeutics after trial discontinuation
- Pliant Therapeutics downgraded to Market Perform from Outperform at Leerink
- Pliant Therapeutics price target lowered to $17 from $40 at Piper Sandler
- Pliant Therapeutics discontinues BEACON-IPF Phase 2b trial of bexotegrast
- Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Cheat Sheet